Essential Thrombocythemia clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Our lead scientists for Essential Thrombocythemia research studies include Angela G. Fleischman.